Answers are grounded in this paper and cite their sources.
An observed decline in the incidence of Kaposi’s sarcoma (KS) in HIV patients has been attributed to the use of highly active antiretroviral therapy (HAA RT) [1]. Furthermore, a number of reports have documented cutaneous KS lesion regression after the initiation of HAART, and this effect appears to be linked to the restoration of immune function [2]. Recently, patients with recurrence or development of mucocutaneous KS during initial or long-term viro-immunological response to HAART were described. In these patients an intensification of HAART failed to control KS lesions [3]. A strong association was observed between the extent of KS disease and the levels of human herpesvirus 8 (HHV8) DNA in peripheral blood mononuclear cells (PBMC), providing further evidence for a relationship between HHV8 virus load and KS pathogenesis [4]. Anecdotal reports exist on the efficacy of cidofovir on HHV8 in vitro[5], and on HHV8 cytoviraemia and KS lesions [6]. We describe the effect of cidofovir treatment on KS cutaneous lesions and HHV8 cytoviraemia in two KS AIDS patients, who experienced the emergence of multiple cutaneous new KS lesions despite long-term efficient HAART (patient A, stavudine, didanosine and saquinavir for 31 months; patient B, stavudine, zalcitabine and saquinavir for 11 months). Before starting cidofovir treatment, multiple-agent cytotoxic chemotherapy (vinblastine, vincristine and IFN-α) was attempted in both patients, without any therapeutic efficacy on KS lesions. Cidofovir was administered at a dose of 5 mg/kg intravenously at one week intervals for the first two administrations and every 2 weeks thereafter. The overall cidofovir treatment period was 10 months for patient A and 12 months for patient B. Table 1 shows the viro-immunological HIV parameters, time of cidofovir treatment, HHV8 antilytic-antigen serum antibody titre by immunofluorescent assay, and HHV8 DNA in PBMC using qualitative polymerase chain reaction.Table 1: Virological and immunological parameters in two patients during cidofovir treatment. During the first period of cidofovir treatment, HIV plasma viraemia rebounded in both subjects. We observed an important regression of all cutaneous KS lesions after 3 months of treatment. HHV8 cytoviraemia became undetectable during cidofovir treatment and correlated with clinical improvement. No adverse reactions occurred during therapy with cidofovir. Treatment was stopped after a 6 and 8 month period free of KS recurrence for patients A and B, respectively. Two months after interruption of cidofovir treatment, HHV8-DNA cytoviraemia rebounded in patient B. Antibody titres against HHV8 remained strongly positive. Reactivation or new KS lesions were not observed until 6 and 15 months after the end of treatment for patients A and B, respectively. Cidofovir is a broad-spectrum antiviral drug and shows marked in-vitro activity against HHV8. Our findings suggest that cidofovir reduces the HHV8 replication in PBMC of KS patients, and it is likely that the drug has a direct effect on HHV8 infected tumour cells. In our experience, cidofovir treatment may be considered in KS recurrence in HIV patients treated with HAART. In our patients, cidofovir was shown to be safe and efficient in the control of KS lesions in a short follow-up period after therapy.
No takes yet. Share an insight, caveat, or question.
Mazzi et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: